Press Releases

05-06 AbbVie to Present at the Bank of America Securities Healthcare Conference PR
05-05 AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week® PR
05-04 SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis AQ
04-30 AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec GL
04-30 Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month PR
04-29 AbbVie : ABBV 1Q26 Press Release Final PU
04-29 AbbVie: Q1 Earnings Snapshot AQ
04-29 AbbVie Reports First-Quarter 2026 Financial Results PR
04-28 AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata PR
04-28 RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor AQ
04-27 AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease PR
04-24 AbbVie Provides Update on TrenibotulinumtoxinE Biologics License Application in the U.S. AQ
04-23 AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. PR
04-22 AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus PR
04-20 AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada AQ
04-14 Erin Lichy Gets Real About Her Natrelle® Breast Augmentation PR
04-13 AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026 AQ
04-12 AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 PR
04-09 BOTOX(R) Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through 'The Confidence Collective' for Fourth Year AQ
04-08 AbbVie : moves to close loopholes and strengthen accountability in 340B program PU
04-08 BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year PR
04-08 AbbVie Defeats Genetic Privacy Class Action Because Request For Plaintiff's Family Medical History Was Not A "Condition Of Employment" AQ
04-07 Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin PR
03-31 /C O R R E C T I O N -- AbbVie/ PR
03-31 AbbVie to Host First-Quarter 2026 Earnings Conference Call PR
No results for this search